Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-blinded, Active-controlled Parallel Group Efficacy and Safety Study of GK530G Versus CD0271 0.1% Gel and CD1579 2.5% Gel in the Treatment of Acne Vulgaris.

Next Previous
Trial Profile

A Multicenter, Randomized, Double-blinded, Active-controlled Parallel Group Efficacy and Safety Study of GK530G Versus CD0271 0.1% Gel and CD1579 2.5% Gel in the Treatment of Acne Vulgaris.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 01 Apr 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adapalene/benzoyl peroxide (Primary) ; Adapalene; Benzoyl peroxide
  • Indications Acne vulgaris
  • Focus Registrational; Therapeutic Use
  • Sponsors Galderma

Most Recent Events

  • 05 Jul 2016 According to a Galderma Pharma media release, based on this and other trial (700235438) the Japan Ministry of Health, Labor and Welfare has approved Epiduo, a for the treatment of acne vulgaris in Japan.
  • 17 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
  • 16 Jun 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top